- Home
- GCTS vs CNTX Comparison
GCTS vs CNTX Comparison
Compare GCTS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- CNTX
- Stock Information
- Founded
- GCTS 1998
- CNTX 2015
- Country
- GCTS United States
- CNTX United States
- Employees
- GCTS N/A
- CNTX N/A
- Industry
- GCTS Blank Checks
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- GCTS Finance
- CNTX Health Care
- Exchange
- GCTS Nasdaq
- CNTX Nasdaq
- Market Cap
- GCTS 73.7M
- CNTX 75.6M
- IPO Year
- GCTS N/A
- CNTX 2021
- Fundamental
- Price
- GCTS $1.45
- CNTX $1.13
- Analyst Decision
- GCTS Strong Buy
- CNTX Strong Buy
- Analyst Count
- GCTS 1
- CNTX 7
- Target Price
- GCTS $5.00
- CNTX $5.20
- AVG Volume (30 Days)
- GCTS 345.4K
- CNTX 260.4K
- Earning Date
- GCTS 11-13-2025
- CNTX 11-05-2025
- Dividend Yield
- GCTS N/A
- CNTX N/A
- EPS Growth
- GCTS N/A
- CNTX N/A
- EPS
- GCTS N/A
- CNTX N/A
- Revenue
- GCTS $6,073,000.00
- CNTX N/A
- Revenue This Year
- GCTS N/A
- CNTX N/A
- Revenue Next Year
- GCTS $1,597.96
- CNTX N/A
- P/E Ratio
- GCTS N/A
- CNTX N/A
- Revenue Growth
- GCTS N/A
- CNTX N/A
- 52 Week Low
- GCTS $0.90
- CNTX $0.49
- 52 Week High
- GCTS $2.86
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- GCTS 47.41
- CNTX 69.12
- Support Level
- GCTS $1.39
- CNTX $0.98
- Resistance Level
- GCTS $1.81
- CNTX $1.29
- Average True Range (ATR)
- GCTS 0.10
- CNTX 0.09
- MACD
- GCTS -0.02
- CNTX 0.02
- Stochastic Oscillator
- GCTS 18.79
- CNTX 65.91
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.